MXPA03011521A - Aminadioles para tratamiento de enfermedad de alzheimer. - Google Patents
Aminadioles para tratamiento de enfermedad de alzheimer.Info
- Publication number
- MXPA03011521A MXPA03011521A MXPA03011521A MXPA03011521A MXPA03011521A MX PA03011521 A MXPA03011521 A MX PA03011521A MX PA03011521 A MXPA03011521 A MX PA03011521A MX PA03011521 A MXPA03011521 A MX PA03011521A MX PA03011521 A MXPA03011521 A MX PA03011521A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- alzheimer
- aminediols
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion se refiere a compuestos de formula, empleados en el tratamiento de la enfermedad de Alzheimer y otras enfermedades similares. Estos compuestos incluyen inhibidores de la enzima betasecretasa que son empleados en el tratamiento de la enfermedad de Alzheimer y otras enfermedades, caracterizados por la deposicion de peptido A beta en un mamifero. Los compuestos de la invencion son empleados en composiciones farmaceuticas y metodos de tratamiento para reducir la formacion del peptido A beta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29782701P | 2001-06-13 | 2001-06-13 | |
US33308401P | 2001-11-19 | 2001-11-19 | |
PCT/US2002/018845 WO2002100818A2 (en) | 2001-06-13 | 2002-06-13 | Aminediols as agents for the treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03011521A true MXPA03011521A (es) | 2004-03-18 |
Family
ID=26970331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03011521A MXPA03011521A (es) | 2001-06-13 | 2002-06-13 | Aminadioles para tratamiento de enfermedad de alzheimer. |
Country Status (7)
Country | Link |
---|---|
US (1) | US6906104B2 (es) |
EP (1) | EP1395251A2 (es) |
JP (1) | JP2004532894A (es) |
AU (1) | AU2002315131A1 (es) |
CA (1) | CA2450205A1 (es) |
MX (1) | MXPA03011521A (es) |
WO (1) | WO2002100818A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989276B2 (en) * | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
USRE44031E1 (en) | 2001-05-10 | 2013-02-26 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
US7695919B2 (en) * | 2001-05-10 | 2010-04-13 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
EP1453792B1 (en) * | 2001-11-19 | 2007-04-18 | Elan Pharmaceuticals, Inc. | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease |
CN1732161A (zh) * | 2002-09-06 | 2006-02-08 | 艾伦药物公司 | 1,3-二氨基-2-羟基丙烷前体药物衍生物 |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US7727752B2 (en) * | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
US20070196860A1 (en) * | 2006-01-18 | 2007-08-23 | Invitrogen Corporation | Methods for Measuring Real Time Kinase Activity |
US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
US20080300796A1 (en) * | 2007-05-31 | 2008-12-04 | Lassahn Gordon D | Biological analysis methods, biological analysis devices, and articles of manufacture |
US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
US20110098309A1 (en) * | 2007-07-12 | 2011-04-28 | Acumen Pharmaceuticals, Inc. | Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
US20100286164A1 (en) * | 2007-10-12 | 2010-11-11 | The Brigham And Women's Hospital, Inc | Substituted aryl alkylamino-oxy-analogs and uses thereof |
CA2707309A1 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5721131A (en) | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
CA2085127C (en) | 1990-06-15 | 2002-12-10 | Barbara Cordell | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
WO1992013069A1 (en) | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0620849B1 (en) | 1992-01-07 | 2003-06-25 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5399763A (en) * | 1993-02-01 | 1995-03-21 | Nippon Kayaku Kabushiki Kaisha | Process for preparing optically active 2-aminopropanal |
ZA945719B (en) * | 1993-08-09 | 1996-02-01 | Lilly Co Eli | Identification and use of protease inhibitors |
DE69426571T2 (de) | 1993-10-27 | 2001-08-09 | Elan Pharm Inc | TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US5728718A (en) * | 1994-12-20 | 1998-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same |
US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
US5763464A (en) * | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
JP2001503643A (ja) | 1996-11-20 | 2001-03-21 | オクラホマ メディカル リサーチ ファウンデーション | アスパラギン酸プロテアーゼの一種であるナプシンのクローニングおよび特徴付け |
US6191166B1 (en) | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US5962506A (en) * | 1997-07-07 | 1999-10-05 | Pharmacopeia, Inc. | Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases |
GB9812189D0 (en) | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
KR20070013361A (ko) | 1998-09-24 | 2007-01-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
US6475659B1 (en) * | 1998-11-17 | 2002-11-05 | C&D Charter Holdings Inc. | Selectable capacity fixed footprint lead-acid battery racking system with horizontal plates |
NZ534876A (en) | 1999-02-10 | 2006-02-24 | Elan Pharm Inc | Human beta-secretase enzyme, inhibitors and their compositions and uses |
AU7757400A (en) | 1999-08-09 | 2001-03-05 | Vanderbilt University | Antiviral therapy use of p-glycoprotein modulators |
CA2397786A1 (en) | 1999-09-23 | 2001-04-05 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
JP2002370183A (ja) * | 2001-06-15 | 2002-12-24 | Yamaha Motor Co Ltd | 監視装置及び監視システム |
-
2002
- 2002-06-13 JP JP2003503588A patent/JP2004532894A/ja active Pending
- 2002-06-13 US US10/171,343 patent/US6906104B2/en not_active Expired - Fee Related
- 2002-06-13 EP EP02742074A patent/EP1395251A2/en not_active Withdrawn
- 2002-06-13 CA CA002450205A patent/CA2450205A1/en not_active Abandoned
- 2002-06-13 WO PCT/US2002/018845 patent/WO2002100818A2/en active Application Filing
- 2002-06-13 MX MXPA03011521A patent/MXPA03011521A/es not_active Application Discontinuation
- 2002-06-13 AU AU2002315131A patent/AU2002315131A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2004532894A (ja) | 2004-10-28 |
US6906104B2 (en) | 2005-06-14 |
WO2002100818A3 (en) | 2003-09-25 |
US20030092747A1 (en) | 2003-05-15 |
WO2002100818A2 (en) | 2002-12-19 |
CA2450205A1 (en) | 2002-12-19 |
EP1395251A2 (en) | 2004-03-10 |
AU2002315131A1 (en) | 2002-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
TNSN04017A1 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | |
MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
MXPA04003245A (es) | Hidroxipropilaminas. | |
MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
EP1689713A4 (en) | BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | |
MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
WO2004029019A3 (en) | Compounds for the treatment of alzheimer’s disease | |
WO2002094768A3 (en) | Aza hydroxylated ethyl amine compounds | |
AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
WO2005042472A3 (en) | Hydroxypropyl amides for the treatment of alzheimer’s disease | |
ECSP044940A (es) | N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |